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Identity 
Other names: CBP (cAMP Response Element-
Binding Protein (CREB)-binding protein); RSTS 
(Rubinstein-Taybi syndrome); KAT3A 





A: CBP (16p22) - Courtesy Mariano Rocchi, Resources for 
Molecular Cytogenetics. Laboratories willing to validate the 
probes are welcome : contact rocchi@biologia.uniba.it.  
B: Map showing the position of BAC clone RP11-1072J2 
(UCSC Genome Browser assembly Mar 2006), centered on 
CREBBP gene (top) and two images of partial metaphases 
from normal controls showing, after FISH, CREBBP-specific 





The gene spans about 155 kb; transcription from 
centromere to telomere, number of exons: 31. 
Transcription 
10 kb mRNA, with a 7.3 kb coding sequence, start 
codon in exon 1, stop codon in exon 31. 
Protein 
Description 
2442 amino acids; 265351 Da; predict PI=8.83; Known 
domains are: KIX= CREB binding, Bromo= 
Bromodomain, Zn=zinc-finger (corresponding to 
cysteine-histidine rich regions), HAT= acetyl 
transferasic, Q= poly Glutaminic stretch. From the 
carboxy to the N-terminus: Q-Zn-HAT-Zn-Bromo-
KIX-Zn. Reported isoform b (2402 aa) lacking aa406-
444 (exon 5). Methylation of the KIX domain by 
CARM1 blocks association with CREB. 
Phosphorylated upon DNA damage, probably by ATM 
or ATR. 
Expression 
Wide expression; expression in the whole embryo as 
well brain; cDNA sources: mammary gland; lung; 
placenta; testis; lymph node; thymus; mouth; ear; 
kidney; embryonic tissue; larynx; pancreas; intestine; 
blood; heart; amniotic fluid; trachea; liver; thyroid; 
skin; connective tissue; uterus; eye; prostate; stomach; 
ovary; salivary gland; muscle; adrenal gland; bone 
marrow; adipose tissue; spleen; nerve; bone; bladder. 










Binds specifically to phosphorylate CREB and 
enhances its transcriptional activity toward cAMP-
responsive genes; 
Acts as transcription co-activator by: i) enabling the 
interaction between different TF and RNAPolII 
complexes, ii) serving as molecular scaffold that brings 
enzymes to the promoter, iii) remodelling the 
chromatin favouring the open status, by histone and
non-histone proteins acetylation. 
Essential role in embryogenesis, cell differentiation, 
apoptosis, and proliferation; 





t(8;16)(p11;p13)/M4 ANLL --> MOZ/CBP 
Disease 
Acute non lymphocytic leukemia (ANLL) and 
treatment related ANLL (t-ANLL). 
Prognosis 
Poor: remission is obtained in half cases; survival s 
often less than 1yr. 
Cytogenetics 
+8 as an additional anomalies in half cases. 
Hybrid/Mutated gene 
5' MOZ - 3' CBP. 
Abnormal protein 
N-term finger motifs and acetyl transferase from MOZ 
fused to most of CBP, with a breakpoint in 5' of the 
CREB binding domain of CBP. 
 
Top: Ideogram of chromosome 16 and chromosomal localisation of the CREBBP gene. Middle: the genomic region including CREBBP 
(red) and flanking genes is zoomed. Deletions spanning CREBBP and adjacent sequences (accounting for about 10% of CREBBP 
mutations) are indicated by black lines. Mosaic deletions (only 3 so far detected) are asterisked; dotted lines target low-resolution 
mapped breakpoints. So far 22 deletions have been reported and the differently sized ones (21) are here diagrammed.  
Bottom: structure of CREBBP gene and protein. Different colours are used to link gene exons (pictured by rectangles) and corresponding 
protein domains. Different reported point mutations (n.108 in Leiden Open Variation Database) are shown: filled circles (nonsense) and 
dotted circles (frameshift), squares (missense) and triangles (splicing). Most mutations cluster to exons encoding the HAT domain. 
Known domains from the carbossi-terminal are: Q= poly Glutaminic stretch, Zn=zinc-finger, HAT= acetyl transferasic, Bromo= 
Bromodomain, KIX= CREB binding). 
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t(10;16)(q22;p13)/M4 ANLL --> 
MYST4/CBP 
Disease 
Acute myeloid leukaemia (AML) M4/M5a and 
therapy-related myelodysplastic syndromes (MDS). 
Only 4 cases described. 
Prognosis 
Poor, bad response to chemotherapy. 
Hybrid/Mutated gene 
5' MYST4 - 3' CBP. 
Abnormal protein 
In-frame fusion between MYST4 exon 17 and 
CREBBP exon 3. Variants fusing MYST4 exon 16 and 
CREBBP exon 5; MYST4 exon 17 and CREBBP exon 
7 have been also described. CREBBP-MYST4 
transcripts have been detected. 
t(11;16)(q23;p13)/t-ANLL --> MLL/CBP 
Disease 
Therapy related ANLL (t-ANLL); should be very close 




Likely to be poor. 
Hybrid/Mutated gene 
5' MLL - 3'CBP. 
Abnormal protein 
N-term AT hook and DNA methyltransferase from 
MLL fused to most of CBP; variable brakpoint in CBP: 
either 5' to the CREB binding domain (like in the 
t(8;16)), or just upstream the bromodomain. 
Rubinstein-Taybi syndrome 
Note 
Due to CBP haploinsufficiency. 
Disease 
Rare autosomal dominant congenital disorder 
characterized by postnatal growth retardation and 
psychomotor developmental delay, skeletal anomalies 
(broad and duplicated distal phalanges of thumbs and 
halluces are a landmark sign) and specific facial 
dysmorphisms. The latter include down-slanted 
palpebral fissures, broad nasal bridge, beaked nose and 
micrognathia. In addition, patients with RSTS have n 
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Localization of breakpoints affecting CREBBP and partner genes in leukaemia-associated balanced translocations. 
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